GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Total Payout Ratio

Arbutus Biopharma (Arbutus Biopharma) Total Payout Ratio : 0.41 (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Arbutus Biopharma's current Total Payout Ratio is 0.41.


Arbutus Biopharma Total Payout Ratio Historical Data

The historical data trend for Arbutus Biopharma's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Total Payout Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 1.35 1.77 0.29 0.41

Arbutus Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 1.22 0.28 0.07 0.20

Competitive Comparison of Arbutus Biopharma's Total Payout Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Total Payout Ratio falls into.



Arbutus Biopharma Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Arbutus Biopharma's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 29.852 + 0) / -72.849
=0.41

Arbutus Biopharma's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 3.852 + 0) / -19.312
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arbutus Biopharma Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8